CN1590383A - Rod sage root extract and making method of its preparation - Google Patents
Rod sage root extract and making method of its preparation Download PDFInfo
- Publication number
- CN1590383A CN1590383A CN 03156388 CN03156388A CN1590383A CN 1590383 A CN1590383 A CN 1590383A CN 03156388 CN03156388 CN 03156388 CN 03156388 A CN03156388 A CN 03156388A CN 1590383 A CN1590383 A CN 1590383A
- Authority
- CN
- China
- Prior art keywords
- radix salviae
- salviae miltiorrhizae
- preparation
- miltiorrhizae extract
- total phenolic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A danshinolic acid is prepared from red sage root through extracting in water or low-grade alcohol, filtering to obtain liquid extract, vacuum concentrating at low temp, distilling to remove low-grade alcohol, regulating pH value by inorganic acid, filtering, extracting in polar solvent to generate water layer and solvent layer, gatting solvent layer, concentrating and drying.
Description
Technical field
The present invention relates to the preparation method of a kind of Radix Salviae Miltiorrhizae extract and preparation thereof, refer to the preparation method of the extract and the preparation thereof of Radix Salviae Miltiorrhizae total phenolic acids or its acceptable salt especially, belong to modern Chinese traditional medicine field.
Background technology
The red sage root is the dry root and rhizome of Labiatae Salvia per nnial herb red sage root Salvia miltiorrhiza Bunge.Beginning is stated from Shennong's Herbal, classifies as top grade.The successive dynasties book on Chinese herbal medicine all records, and function is removed stasis of blood pain relieving, promoting blood circulation to restore menstrual flow, relieving restlessness clears away heart-fire.It is tcm clinical practice medicine commonly used.
The chemical ingredients of the red sage root mainly can be divided into water soluble component and fat-soluble component two parts.20th century, early stage research mainly concentrated on the fat-soluble component aspect, and the effort through decades has obtained huge achievement.Obtained with TANSHINONES, Cryptotanshinone is a series of compounds of representative.But traditional administrated method of the traditional Chinese medical science is to use its water decoction, and the widest red sage formulation of clinical application is its injection, i.e. the water-soluble portion of the red sage root.The effective constituent of the prompting red sage root is based on water soluble component.From the eighties in 20th century, China pharmaceuticals researcher studies the water soluble component of the red sage root.Separate and obtained salvianolic acid A, B, C, D, E, F, G, H, I, J, rosmarinic acid, alkannic acid, different salvianolic acid C, phenolic acid compounds such as the glycoside of rosmarinic acid.The pharmacological results explanation Radix Salviae Miltiorrhizae total phenolic acids has to heart, to the provide protection of brain injury; antithrombotic, delay the effect that cataract forms,, suppress the HIV (human immunodeficiency virus) effect the provide protection of liver kidney; improve the blood circulation effect, anti-oxidative damage effect and the effect of enhancing learning and memory etc.Wherein the activity of salviol acid A and B is the strongest.
Because salvianolic acid compounds instability is easily decomposed in preparation and storage process and is gone bad, and the more easily separated and synthetic acquisition of rancinamycin IV and Salvianic acidA.Therefore existing red sage formulation ingredient is mainly active more weak Salvianic acidA and rancinamycin IV, and then content is few to have very strong active phenolic acid, and this has a greatly reduced quality pharmacologically active.
At present, the extracting method of salvianolic acid compounds mostly is with behind the water extraction, through resin column.1989, the extracting method of the salvianolate of reports such as Takashi Tanaka is: red sage root hot water extraction, behind the concentrating under reduced pressure by with vinylbenzene being the macroporous resin MCI-CHP-20P of framework material, after washing with water, use 50% methanol-eluted fractions again, mainly contained the salvianolate of salvianolic acid B magnesium.Thereafter, Koji Hase etc., Xu Yaming etc. (Chinese patent CN 1247855A, 2000 are open), ma Li Lian etc. (Chinese patent CN 1384090A, in December, 2002 is open) successively adopt to use the same method to extract from the red sage root and obtain phenolic acid compound.Above method, adopt macroporous resin as main separation means, at first be difficult to determine organic polymer material such as vinylbenzene residual with and to the situation that influences of gained compound of phenolic acid, secondly, adopt the content of the resulting salvianolic acid compounds of this method lower.The disclosed preparation method of patent CN 1384090A has carried out the alcohol precipitation processing before aqueous extract is crossed macroporous resin column.Though this step has been removed impurity, also make phenolic acid compound that bigger loss has been arranged.
Summary of the invention
The preparation method who the purpose of this invention is to provide a kind of Radix Salviae Miltiorrhizae extract, the i.e. preparation method of Radix Salviae Miltiorrhizae total phenolic acids or its acceptable salt.
Another object of the present invention provides the Radix Salviae Miltiorrhizae extract that obtains with aforesaid method, i.e. Radix Salviae Miltiorrhizae total phenolic acids and its acceptable salt.
The preparation that it is effective constituent with Radix Salviae Miltiorrhizae total phenolic acids or its acceptable salt promptly that a further object of the present invention provides with Radix Salviae Miltiorrhizae extract.
Last purpose of the present invention provides the application of Radix Salviae Miltiorrhizae extract.
For achieving the above object, the present invention is by the following technical solutions:
A kind of preparation method of Radix Salviae Miltiorrhizae extract comprises the following steps:
1) extract: with the red sage root is raw material, and water, lower alcohol or moisture lower alcohol extraction filter, and obtain extracting solution;
2) concentrate: extracting solution is concentrating under reduced pressure at low temperatures, boils off lower alcohol;
3) adjust pH: concentrated solution is adjusted to acidity with mineral acid, filters;
4) extraction: filtrate is handled with polar solvent or mixing polar solvent and is made it form water layer and organic solvent layer;
5) drying: divide and get organic solvent layer, concentrate, drying promptly gets Radix Salviae Miltiorrhizae total phenolic acids.
Described preparation method comprises that also step 6) with the Radix Salviae Miltiorrhizae total phenolic acids dissolving that obtains, with mineral alkali or organic bases neutralization, had both got the acceptable salt of Radix Salviae Miltiorrhizae total phenolic acids.
The carbon number of the moisture lower alcohol of described extraction usefulness is C1-C5, for example: methyl alcohol, ethanol, propyl alcohol, propyl carbinol, isopropylcarbinol etc.; Concentration is X, 0%＜X≤95%, preferred 30%≤X≤50%.
Described concentrated solution is adjusted to acidity with mineral acid and is meant that regulating the pH value is 0-4, and preferred pH value is 2-3.
Described extracting method is selected from a kind of in decoction, backflow, dipping and the diacolation, preferably dipping or diacolation.
Described extraction is with polar solvent or to mix polar solvent be vinyl acetic monomer, propyl carbinol, butanone, or the polar solvent that mixes of these polar solvents and methyl alcohol, ethanol or acetone composition.
This shows that prepare Radix Salviae Miltiorrhizae total phenolic acids or its acceptable salt with the inventive method, technology is simple, does not need specific installation, safety, easy handling, with low cost.The present invention carries out removal of impurities and refining by the method for extraction and regulator solution pH value to extracting solution, compared with prior art, not only overcome the loss of using alcohol precipitating method that salvianolic acid is caused, also avoided using resin method and the residual problem of macromolecular compound that might cause.And gained final product Radix Salviae Miltiorrhizae total phenolic acids content height, impurity is few, and its total phenolic content is more than 90%, and wherein the content of salvianolic acid B accounts for the 70%-95% of total phenolic acid.Therefore gained Radix Salviae Miltiorrhizae total phenolic acids or its acceptable salt have higher and reliable physiologically active.The gained Radix Salviae Miltiorrhizae total phenolic acids is white to buff powder, good appearance, steady quality, reliable.
A kind of Radix Salviae Miltiorrhizae extract, this extract are Radix Salviae Miltiorrhizae total phenolic acids or the Radix Salviae Miltiorrhizae total phenolic acids salt that adopts method for preparing to obtain.
A kind of application of Radix Salviae Miltiorrhizae extract is used to prepare the medicine for the treatment of cardiovascular and cerebrovascular diseases with described Radix Salviae Miltiorrhizae extract.
A kind of Radix Salviae Miltiorrhizae extract preparation, said preparation as main active ingredient, and add the pharmaceutics acceptable auxiliary with Radix Salviae Miltiorrhizae extract, make the pharmaceutics acceptable forms.Described auxiliary material is selected from one or more in starch, Microcrystalline Cellulose, sucrose, dextrin, lactose, Icing Sugar, glucose, sodium-chlor, vitamins C, halfcystine, citric acid and the S-WAT.Described pharmaceutics acceptable forms is oral preparation and injection, as tablet, pill, capsule, dripping pill, powder pin liquid drugs injection or transfusion.The Radix Salviae Miltiorrhizae total phenolic acids powder injection that makes with the inventive method has overcome the defective that the salvianolic acid compounds easily decomposes, goes bad in preparation and storage process, have satisfactory stability, has guaranteed the quality and the curative effect of Radix Salviae Miltiorrhizae total phenolic acids.
When preparing the various formulation of required medicine, can be according to the conventional production method preparation of pharmaceutical field.As the Radix Salviae Miltiorrhizae total phenolic acids that utilizes the inventive method to obtain mixes with one or more carriers, makes corresponding dosage forms then.
Advantage of the present invention is: this method is easy, environmental protection, technological process are simple, does not need specific installation, safety, easy handling and carry out quality control, with low cost, gained Radix Salviae Miltiorrhizae total phenolic acids or Radix Salviae Miltiorrhizae total phenolic acids salts contg height, stable performance is fit to large-scale industrial production.
The invention will be further described below in conjunction with specific embodiment, is not limitation of the present invention.
Embodiment
Embodiment 1
Red rooted salvia 10kg is ground into meal, soaks diacolation after 24 hours, collects 12 times of percolates, concentrates.Add 10%HCL and regulate pH value to 4, filter.Gained filtrate is extracted with 3 times of amount vinyl acetic monomers.The combined ethyl acetate layer.The pressure reducing and steaming ethyl acetate, drying gets Radix Salviae Miltiorrhizae total phenolic acids 314g, and its content is more than 90%.
Embodiment 2
Red rooted salvia 10kg is ground into meal, adds the 50L30% alcohol immersion 24 hours, collects leach liquor, concentrates.Add 15%HCL and regulate pH value to 3, filter.Gained filtrate is extracted with 4 times of amount propyl carbinols.Merge n-butanol layer.The pressure reducing and steaming ethyl acetate, drying gets Radix Salviae Miltiorrhizae total phenolic acids 360g, and its content is more than 90%.
Embodiment 3
Red rooted salvia 10kg is ground into meal, adds the 40L50% alcohol reflux, concentrated extracting solution.Add 5% sulphur acid for adjusting pH value to 0, filter.Gained filtrate is measured ethyl acetate and alcoholic acid mixing solutions (ethyl acetate: ethanol=10: 1) extract with 3 times.Merge organic solvent layer.The pressure reducing and steaming organic solvent, drying gets Radix Salviae Miltiorrhizae total phenolic acids 325g, and its content is more than 90%.
Embodiment 4
Red rooted salvia 10kg is ground into meal, adds the 50L95% alcohol immersion 24 hours, collects leach liquor, concentrates.Add 15%HCL and regulate pH value to 2, filter.With the mixed solution (ethyl acetate: acetone=3: 1) extract of gained filtrate with 4 times of amount ethyl acetate and acetone.Merge organic solvent layer.The pressure reducing and steaming organic solvent, drying gets Radix Salviae Miltiorrhizae total phenolic acids 264g, and its content is more than 90%.
Embodiment 5
Red rooted salvia 10kg is ground into meal, adds the 50L70% alcohol reflux, concentrated extracting solution.Add 10%HCL and regulate pH value to 3, filter.Gained filtrate is extracted with 3 times of amount butanone.Merge the butanone layer.The pressure reducing and steaming butanone, drying gets Radix Salviae Miltiorrhizae total phenolic acids 382g, and its content is more than 90%.
Embodiment 6
Red rooted salvia 10kg is ground into meal, adds the 40L50% alcohol reflux, concentrated extracting solution.Add 5% sulphur acid for adjusting pH value to 0, filter.Gained filtrate is extracted with 3 times of amount acetone.Merge the acetone layer.Pressure reducing and steaming acetone, drying gets Radix Salviae Miltiorrhizae total phenolic acids 325g.Gained Radix Salviae Miltiorrhizae total phenolic acids 100g is added ethanol 150ml be made into strong solution, add 1 ‰ (w/v) gac 10g, room temperature was placed 30 minutes, filtered, cross 0.45 μ millipore filtration to clear and bright, filtrate is transferred pH to 5.5 at aseptic indoor 1% sodium hydroxide ethanol liquid, and precipitation is fully separated out, and leaves standstill, filter, precipitation is used washing with alcohol, decompressing and extracting, and 105 ℃ of vacuum dryings promptly get the Radix Salviae Miltiorrhizae total phenolic acids sodium salt.
Embodiment 7
Get the Radix Salviae Miltiorrhizae total phenolic acids sodium salt aseptic subpackaged injection Radix Salviae Miltiorrhizae total phenolic acids sodium salt powder injection that promptly gets under dry, aseptic, clean environment among the embodiment 6.
Specification: every 500mg.
Consumption: 1～2/time, use for vein or intramuscular injection.
Steady quality of the present invention, dose controlled, pollution-free, be convenient to operation, transportation, storage, be suitable for scale operation
Embodiment 8
Get 1 time Radix Salviae Miltiorrhizae total phenolic acids 300g of embodiment, add starch 400g, Microcrystalline Cellulose 100g, with 50% alcohol granulation, compressing tablet is for making 10000.
Embodiment 9 Radix Salviae Miltiorrhizae total phenolic acidss are to the restraining effect experiment of platelet aggregation
Choose healthy rabbits, male, experiment is divided into 5 groups, i.e. blank group (giving physiological saline); TD (Radix Salviae Miltiorrhizae total phenolic acids) group 40,20,10mg/kg.The auricular vein administration, 30min gets blood and experimentizes behind the medicine.
Get blood (with 3.8% Sodium Citrate anti-freezing, whole blood and antithrombotics are 9: 1) from the rabbit arteria carotis communis, the centrifugal 10min of 800rpm, preparation platelet rich plasma (PRP), centrifugal 10 minutes again, preparation platelet poor plasma (PPP) through 3500rpm.Behind the pre-temperature of blood plasma (37 ℃) 30min, transfer 100%,, add different inductors, measure platelet aggregation percentage ratio with platelet aggregation instrument by turbidimetry with the PRP zeroing with PPP.
(1) to the influence of ADP inductive platelet aggregation
With ADP is the aggregation inducing agent, and the application of sample volume is 3ul, and final concentration is 0.3uM, and the result shows that TD40mg/kg obviously suppresses the hematoblastic aggreation of ADP inductive, and inhibiting rate is 81.5%.
TD to the influence of ADP inductive platelet aggregation (X ± SD, n=5)
Group dosage aggregation rate (%) inhibiting rate (%)
Blank group 2ml/kg 54.0 ± 22.6
TD group 40mg/kg 10.0 ± 5.4* 81.5
TD organizes 20mg/kg 36.4 ± 9.9 32.5
TD organizes 10mg/kg 40.0 ± 34.3 25.9
Red sage root group 40mg/kg 29.3 ± 22.0 45.7
Compare * p＜0.05 with the blank group
Conclusion: TD 40mg/kg obviously suppresses the hematoblastic aggreation of ADP inductive, and inhibiting rate is 81.5%
(2) to the influence of the platelet aggregation of arachidonic acid-induction
With AA is aggregating agent prepared therefrom, and the application of sample volume is 2ul, and final concentration is 0.2mM
Result: TD 40,20mg/kg obviously suppress the hematoblastic aggreation of arachidonic acid-induction, and inhibiting rate is respectively 76.7,32.7%.
TD to the influence of AA inductive platelet aggregation (X ± SD, n=5)
Group dosage aggregation rate (%) inhibiting rate (%)
Blank group 2ml/kg 78.4 ± 17.2
TD group 40mg/kg 20.3 ± 15.6** 74.1
TD group 20mg/kg 56.6 ± 6.8* 27.9
TD organizes 10mg/kg 62.6 ± 32.5 20.3
Red sage root group 40mg/kg 44.0 ± 23.5* 43.9
Compare * p＜0.05, * * p＜0.01 with the blank group
(3) to the influence of collagen-induced platelet aggregation
With collagen is inductor, and the application of sample volume is 3ul, and final concentration is 7.5mg/ml.
The result shows that TD 40mg/kg can obviously suppress collagen-induced hematoblastic aggreation, and inhibiting rate is 68.9%.
To the influence of collagen-induced platelet aggregation (X ± SD, n=5)
Group dosage aggregation rate (%) inhibiting rate (%)
Blank group 2ml/kg 68.8 ± 27.0
TD group 40mg/kg 22.1 ± 11.2* 67.9
TD group 20mg/kg 53.8+19.4 21.8
TD organizes 10mg/kg 68.1 ± 19.2 1.0
Red sage root group 40mg/kg 50.1 ± 28.1 27.1
Compare * p＜0.05 with the blank group
Conclusion: TD 40mg/kg can obviously suppress collagen-induced hematoblastic aggreation, and inhibiting rate is 67.9%
The influence that 10 pairs of rat suppositories of embodiment form
Select the healthy adult rat for use, body weight is at 260+50g, male and female half and half.With 20% urethane (1.2g/kg, ip) anesthesia, it is fixing to lie on the back, separate right common carotid artery and left external jugular vein, be full of heparin-saline (40u/ml) in polyethylene tube (including the long silk thread of the 6cm) tube chamber, an end inserts left external jugular vein, the other end inserts right common carotid artery, through managing internal thread linear flow external jugular vein left, blood flow was fixed as 30 minutes through the conduit time blood during test, in the administration of blood circulation 15min posterior vein by right common carotid artery.Blot with filter paper behind the removal of thromboses behind the blood circulation 30min, claim weight in wet base, will contain thrombus and place 50 ℃ of constant temperature ovens to dry to constant weight (about 24 hours), weighing thrombus dry weight.
Test is established 5 groups, is respectively blank group (giving physiological saline), 3 dosage groups of TD (Radix Salviae Miltiorrhizae total phenolic acids) 60,30,15mg/kg, and danshen powder injection group (60mg/kg) all adopts the femoral vein administration.
The result shows that vein gives the formation that TD can obviously suppress thrombus, compares TD 60,30,15mg/kg weight in wet base descended respectively 38.7% (p＜0.05), 35.5% (p＜0.05), 29.0% (p＞0.05) with control group; Dry weight is divided descended in addition 50% (p＜0.01), 50% (p＜0.05), 33.3% (p＞0.05).
Experimental result (seeing the following form) shows, Radix Salviae Miltiorrhizae total phenolic acids can obviously suppress platelet aggregation due to the different factors, and the formation of laboratory animal thrombus is had significant inhibitory effect.The prompting Radix Salviae Miltiorrhizae total phenolic acids with and the using value of preparation in cardiovascular and cerebrovascular diseases.
TD to the influence of the formation of thrombus (X+SD, n=12)
Group dosage weight in wet base (mg) dry weight (mg)
Blank group 3ml/kg 31 ± 14 6+3
TD group 60mg/kg 19 ± 10* 3 ± 2**
TD group 30mg/kg 20 ± 11* 3 ± 2*
TD organizes 15mg/kg 22 ± 10 4 ± 3
Red sage root group 60mg/kg 22 ± 14 3 ± 2
Compare * * p＜0.01, * p＜0.05 with the blank group
Claims (15)
1. the preparation method of a Radix Salviae Miltiorrhizae extract comprises the following steps:
1) extract: with the red sage root is raw material, and water, lower alcohol or moisture lower alcohol extraction filter, and obtain extracting solution;
2) concentrate: extracting solution is concentrating under reduced pressure at low temperatures, boils off lower alcohol;
3) adjust pH: concentrated solution is adjusted to acidity with mineral acid, filters;
4) extraction: filtrate is handled with polar solvent or mixing polar solvent and is made it form water layer and organic solvent layer;
5) drying: divide and get organic solvent layer, concentrate, drying promptly gets Radix Salviae Miltiorrhizae total phenolic acids.
2. the preparation method of Radix Salviae Miltiorrhizae extract according to claim 1 is characterized in that: described preparation method also comprises step 6) with the Radix Salviae Miltiorrhizae total phenolic acids dissolving that obtains, with mineral alkali or organic bases neutralization, both the acceptable salt of Radix Salviae Miltiorrhizae total phenolic acids.
3. the preparation method of Radix Salviae Miltiorrhizae extract according to claim 1, it is characterized in that: the carbon number of the moisture lower alcohol of described extraction usefulness is C1-C5, concentration is X, 0%＜X≤95%.
4. the preparation method of Radix Salviae Miltiorrhizae extract according to claim 3, it is characterized in that: described moisture lower alcohol is preferably ethanol, and concentration is X, 30%≤X≤50%.
5. the preparation method of Radix Salviae Miltiorrhizae extract according to claim 1 is characterized in that: described concentrated solution is adjusted to acidity with mineral acid and is meant that regulating the pH value is 0-4.
6. the preparation method of Radix Salviae Miltiorrhizae extract according to claim 5 is characterized in that: described pH value is 2-3.
7. the preparation method of Radix Salviae Miltiorrhizae extract according to claim 1 is characterized in that: described extracting method is selected from a kind of in decoction, backflow, dipping and the diacolation.
8. the preparation method of Radix Salviae Miltiorrhizae extract according to claim 7 is characterized in that: described extracting method is dipping or diacolation.
9. the preparation method of Radix Salviae Miltiorrhizae extract according to claim 1, it is characterized in that: described extraction is with polar solvent or to mix polar solvent be vinyl acetic monomer, propyl carbinol or butanone, or the polar solvent that mixes of these polar solvents and methyl alcohol, ethanol or acetone composition.
10. Radix Salviae Miltiorrhizae extract is characterized in that: this extract is Radix Salviae Miltiorrhizae total phenolic acids or the Radix Salviae Miltiorrhizae total phenolic acids salt that adopts claim 1 or 2 described methods to prepare.
11. a Radix Salviae Miltiorrhizae extract preparation is characterized in that: said preparation as main active ingredient, and adds the pharmaceutics acceptable auxiliary with the described Radix Salviae Miltiorrhizae extract of claim 10, makes the pharmaceutics acceptable forms.
12. Radix Salviae Miltiorrhizae extract preparation according to claim 11 is characterized in that: described auxiliary material is selected from one or more in starch, Microcrystalline Cellulose, sucrose, dextrin, lactose, Icing Sugar, glucose, sodium-chlor, vitamins C, halfcystine, citric acid and the S-WAT.
13. Radix Salviae Miltiorrhizae extract preparation according to claim 11 is characterized in that: described pharmaceutics acceptable forms is oral preparation or injection.
14. Radix Salviae Miltiorrhizae extract preparation according to claim 13 is characterized in that: described oral preparation or injection are tablet, pill, capsule, dripping pill, powder pin liquid drugs injection or transfusion.
15. the application of a Radix Salviae Miltiorrhizae extract is characterized in that: the described Radix Salviae Miltiorrhizae extract of claim 10 is used to prepare the medicine for the treatment of cardiovascular and cerebrovascular diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031563880A CN100484929C (en) | 2003-09-05 | 2003-09-05 | Rod sage root extract and making method of its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031563880A CN100484929C (en) | 2003-09-05 | 2003-09-05 | Rod sage root extract and making method of its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1590383A true CN1590383A (en) | 2005-03-09 |
| CN100484929C CN100484929C (en) | 2009-05-06 |
Family
ID=34598398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031563880A Expired - Fee Related CN100484929C (en) | 2003-09-05 | 2003-09-05 | Rod sage root extract and making method of its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100484929C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100378088C (en) * | 2005-10-12 | 2008-04-02 | 正大青春宝药业有限公司 | Preparation method of red sage root total phenolic acid |
| CN101357886B (en) * | 2007-08-03 | 2010-07-14 | 河北柏奇药业有限公司 | 3-hydroxy benzoate preparation method |
| CN101926848A (en) * | 2009-06-19 | 2010-12-29 | 天津药物研究院 | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof |
| CN101342236B (en) * | 2007-07-11 | 2011-07-20 | 天津药物研究院 | Method for preparing red sage root extract, red sage root extract and medicament composition containing the same |
| CN101757105B (en) * | 2010-02-23 | 2012-05-23 | 广州汉方现代中药研究开发有限公司 | Extraction method capable of enriching fat soluble and water soluble parts of salvia simultaneously |
| CN104529964A (en) * | 2014-12-29 | 2015-04-22 | 北京威力格生物科技有限公司 | Method for effectively extracting total salvianolic acids from salviae miltiorrhizae |
| CN105963705A (en) * | 2016-06-13 | 2016-09-28 | 湖北文理学院 | Compound stabilizer for preserving gingerol and use method of compound stabilizer |
-
2003
- 2003-09-05 CN CNB031563880A patent/CN100484929C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100378088C (en) * | 2005-10-12 | 2008-04-02 | 正大青春宝药业有限公司 | Preparation method of red sage root total phenolic acid |
| CN101342236B (en) * | 2007-07-11 | 2011-07-20 | 天津药物研究院 | Method for preparing red sage root extract, red sage root extract and medicament composition containing the same |
| CN101357886B (en) * | 2007-08-03 | 2010-07-14 | 河北柏奇药业有限公司 | 3-hydroxy benzoate preparation method |
| CN101926848A (en) * | 2009-06-19 | 2010-12-29 | 天津药物研究院 | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof |
| CN101926848B (en) * | 2009-06-19 | 2013-03-20 | 天津药物研究院 | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof |
| CN101757105B (en) * | 2010-02-23 | 2012-05-23 | 广州汉方现代中药研究开发有限公司 | Extraction method capable of enriching fat soluble and water soluble parts of salvia simultaneously |
| CN104529964A (en) * | 2014-12-29 | 2015-04-22 | 北京威力格生物科技有限公司 | Method for effectively extracting total salvianolic acids from salviae miltiorrhizae |
| CN105963705A (en) * | 2016-06-13 | 2016-09-28 | 湖北文理学院 | Compound stabilizer for preserving gingerol and use method of compound stabilizer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100484929C (en) | 2009-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1202103C (en) | Preparation method of red sageroot total phenolic acid and its use | |
| CN110538189A (en) | Eucommia ulmoides extract composition for treating renal fibrosis and application thereof | |
| CN113413392A (en) | Eucommia ulmoides extract composition and preparation method and application thereof | |
| CN102526315A (en) | Preparation method of extracts of effective fractions of lychee seeds | |
| CN112870236A (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
| CN111317750A (en) | Application of sweetsop seed total lactone in preparing medicine for preventing and treating diabetes | |
| CN108888669B (en) | Preparation method of oral liquid for clearing heat and relieving cough of children | |
| CN1590383A (en) | Rod sage root extract and making method of its preparation | |
| CN1449761A (en) | Medicine for relieving spasm and pain and preparation process thereof | |
| CN110496148B (en) | Eucommia ulmoides extract composition for treating gestational hypertension and application thereof | |
| CN1853688A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN1698717A (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN101647858B (en) | Preparation method of water-soluble extract of red sage root | |
| CN1254252C (en) | Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method | |
| CN1291727C (en) | Chinese medicinal composition for treating cardiovascular disease, preparation and use thereof | |
| CN1899388A (en) | Shuangdan soft capsule and its preparing method | |
| CN1817356A (en) | Production of vermilion injection for treating cardiovascular disease | |
| CN1557403A (en) | Medicine for treating angiocardiopathy and cerebrovascular disease and its preparing method | |
| CN112107606B (en) | Application of Chinese parsley or extract thereof in preparation of antidepressant drug | |
| CN1939390A (en) | Medicinal composition and its making method | |
| CN101721468A (en) | Method for preparing salvianolic acids | |
| CN1297568C (en) | Echinacea polysaccharide, and its preparing method and use for preparing medicines for treating antivirus and antibacterial, especially anti SARS | |
| CN1670026A (en) | Lotus plumule alkaloid extract and its preparation process and use in preparation of drugs for cardiovascular and cerebrovascular diseases | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN105596935B (en) | Mongolian medicine compound preparation for intervening or improving diabetic nephropathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN TAIPU PHARMACEUTICAL INTELLECTUAL PROPERTY Free format text: FORMER OWNER: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH Effective date: 20130130 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130130 Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Taipu Pharmaceutical Intellectual Property Flow Reserve Center Co, Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research |
|
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH Free format text: FORMER OWNER: TIANJIN TAIPU PHARMACEUTICAL INTELLECTUAL PROPERTY TRANSFER RESERVE CENTER CO., LTD. Effective date: 20140505 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140505 Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Institute of Pharmaceutical Research Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Taipu Pharmaceutical Intellectual Property Flow Reserve Center Co, Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090506 Termination date: 20170905 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |